Skip to main content

Articles

Page 1 of 103

  1. Metaplastic breast carcinoma (MpBC) typically consists of carcinoma of no special type (NST) with various metaplastic components. Although previous transcriptomic and proteomic studies have reported subtype-re...

    Authors: Huang-Chun Lien, Chia-Lang Hsu, Yen-Shen Lu, Tom Wei-Wu Chen, I.-Chun Chen, Yu-Chia Li, Chiun-Sheng Huang, Ann-Lii Cheng and Ching-Hung Lin
    Citation: Breast Cancer Research 2023 25:11
  2. Necroptosis is a form of regulated necrosis and is executed by MLKL when MLKL is engaged in triggering the rupture of cell plasma membrane. MLKL activation also leads to the protease, ADAMs-mediated ectodomain...

    Authors: Zhaoshan Liu, Swati Choksi, Hyung-Joon Kwon, Delong Jiao, Chengyu Liu and Zheng-gang Liu
    Citation: Breast Cancer Research 2023 25:10
  3. Breast cancer is the most common cancer among women with limited treatment options. To identify promising drug targets for breast cancer, we conducted a systematical Mendelian randomization (MR) study to scree...

    Authors: Yu Wang, Fanghua Liu, Lulu Sun, Yiming Jia, Pinni Yang, Daoxia Guo, Mengyao Shi, Aili Wang, Guo-Chong Chen, Yonghong Zhang and Zhengbao Zhu
    Citation: Breast Cancer Research 2023 25:9
  4. Guidelines recommend shared decision making (SDM) for mammography screening for women ≥ 75 and not screening women with < 10-year life expectancy. High-quality SDM requires consideration of women’s breast canc...

    Authors: Mara A. Schonberg, Emily A. Wolfson, A. Heather Eliassen, Kimberly A. Bertrand, Yurii B. Shvetsov, Bernard A. Rosner, Julie R. Palmer and Long H. Ngo
    Citation: Breast Cancer Research 2023 25:8
  5. Breast cancer survival in South Africa is low, but when diagnosed with breast cancer, many women in South Africa also have other chronic conditions. We investigated the impact of multimorbidity (≥ 2 other chro...

    Authors: Oluwatosin A. Ayeni, Maureen Joffe, Witness Mapanga, Wenlong Carl Chen, Daniel S. O’Neil, Boitumelo Phakathi, Sarah Nietz, Ines Buccimazza, Sharon Čačala, Laura W. Stopforth, Judith S. Jacobson, Katherine D. Crew, Alfred I. Neugut, Duvern Ramiah, Paul Ruff, Herbert Cubasch…
    Citation: Breast Cancer Research 2023 25:7
  6. A challenge in human mammary epithelial cell (HMEC) culture is sustaining the representation of competing luminal, myoepithelial, and progenitor lineages over time. As cells replicate in culture, myoepithelial...

    Authors: Michael E. Todhunter, Masaru Miyano, Eric G. Carlson, Stefan Hinz and Mark A. LaBarge
    Citation: Breast Cancer Research 2023 25:6
  7. Breast cancer incidence rates have not declined despite an improvement in risk prediction and the identification of modifiable risk factors, suggesting the need to identify novel risk factors and etiological p...

    Authors: Victoria L. Stevens, Brian D. Carter, Eric J. Jacobs, Marjorie L. McCullough, Lauren R. Teras and Ying Wang
    Citation: Breast Cancer Research 2023 25:5
  8. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have been established as a standard treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast ca...

    Authors: Chang Gon Kim, Min Hwan Kim, Jee Hung Kim, Seul-Gi Kim, Gun Min Kim, Tae Yeong Kim, Won-Ji Ryu, Jee Ye Kim, Hyung Seok Park, Seho Park, Young Up Cho, Byeong Woo Park, Seung Il Kim, Joon Jeong and Joohyuk Sohn
    Citation: Breast Cancer Research 2023 25:4
  9. The chemotherapy of triple-negative breast cancer based on doxorubicin (DOX) regimens suffers from great challenges on toxicity and autophagy raised off-target. In this study, a conjugate methotrexate-polyethy...

    Authors: Zhiwen Cao, Rui Liu, Yang Li, Xinyi Luo, Zhenglai Hua, Xiangpeng Wang, Zeyu Xue, Zhengjia Zhang, Cheng Lu, Aiping Lu and Yuanyan Liu
    Citation: Breast Cancer Research 2023 25:3
  10. KRISTINE is an open-label, phase III study of trastuzumab emtansine + pertuzumab (T-DM1 + P) versus docetaxel + carboplatin + trastuzumab + pertuzumab (TCH + P) in patients with HER2-positive, stage II–III bre...

    Authors: Sanne L. de Haas, Dennis J. Slamon, Miguel Martin, Michael F. Press, Gail D. Lewis, Chiara Lambertini, Aleix Prat, Vanesa Lopez-Valverde, Thomas Boulet and Sara A. Hurvitz
    Citation: Breast Cancer Research 2023 25:2
  11. Breast cancer mortality is principally due to recurrent disease that becomes resistant to therapy. We recently identified copy number (CN) gain of the putative membrane progesterone receptor PAQR8 as one of four ...

    Authors: Saisai Chen, Matt R. Paul, Christopher J. Sterner, George K. Belka, Dezhen Wang, Peining Xu, Amulya Sreekumar, Tien-chi Pan, Dhruv K. Pant, Igor Makhlin, Angela DeMichele, Clementina Mesaros and Lewis A. Chodosh
    Citation: Breast Cancer Research 2023 25:1
  12. This systematic review aimed to assess the methods used to classify mammographic breast parenchymal features in relation to the prediction of future breast cancer. The databases including Medline (Ovid) 1946-,...

    Authors: Akila Anandarajah, Yongzhen Chen, Graham A. Colditz, Angela Hardi, Carolyn Stoll and Shu Jiang
    Citation: Breast Cancer Research 2022 24:101
  13. After many years of neglect in the field of alternative splicing, the importance of intron retention (IR) in cancer has come into focus following landmark discoveries of aberrant IR patterns in cancer. Many so...

    Authors: Jaynish S. Shah, Michael J. G. Milevskiy, Veronika Petrova, Amy Y. M. Au, Justin J. L. Wong, Jane E. Visvader, Ulf Schmitz and John E. J. Rasko
    Citation: Breast Cancer Research 2022 24:100
  14. Breast cancer (BC) has been ranked the most common malignant tumor throughout the world and is also a leading cause of cancer-related deaths among women. SRC family kinases (SFKs) belong to the non-receptor ty...

    Authors: Juan Luo, Hailin Zou, Yibo Guo, Tongyu Tong, Liping Ye, Chengming Zhu, Liang Deng, Bo Wang, Yihang Pan and Peng Li
    Citation: Breast Cancer Research 2022 24:99
  15. Breast cancer is the most diagnosed cancer among women. Approximately 15–20% of all breast cancers are highly invasive triple-negative breast cancer (TNBC) and lack estrogen, progesterone, and ERBB2 receptors....

    Authors: Natalie S. Joe, Inês Godet, Nubaira Milki, Noor U. I. Ain, Harsh H. Oza, Gregory J. Riggins and Daniele M. Gilkes
    Citation: Breast Cancer Research 2022 24:98
  16. A preoperative-progesterone intervention increases disease-free survival in patients with breast cancer, with an unknown underlying mechanism. We elucidated the role of non-coding RNAs in response to progester...

    Authors: Neelima Yadav, Roma Sunder, Sanket Desai, Bhasker Dharavath, Pratik Chandrani, Mukul Godbole and Amit Dutt
    Citation: Breast Cancer Research 2022 24:97
  17. Dense breast notification (DBN) legislation aims to increase a woman’s awareness of her personal breast density and the implications of having dense breasts for breast cancer detection and risk. This informati...

    Authors: Erica J. Lee Argov, Carmen B. Rodriguez, Mariangela Agovino, Ying Wei, Rachel C. Shelton, Rita Kukafka, Karen M. Schmitt, Elise Desperito, Mary Beth Terry and Parisa Tehranifar
    Citation: Breast Cancer Research 2022 24:95
  18. During cancer development, the normal tissue microenvironment is shaped by tumorigenic events. Inflammatory mediators and immune cells play a key role during this process. However, which molecular features mos...

    Authors: Philémon Sirven, Lilith Faucheux, Maximilien Grandclaudon, Paula Michea, Anne Vincent-Salomon, Fatima Mechta-Grigoriou, Alix Scholer-Dahirel, Maude Guillot-Delost and Vassili Soumelis
    Citation: Breast Cancer Research 2022 24:94
  19. Breast cancer (BC) grading plays a critical role in patient management despite the considerable inter- and intra-observer variability, highlighting the need for decision support tools to improve reproducibilit...

    Authors: Gerardo Fernandez, Marcel Prastawa, Abishek Sainath Madduri, Richard Scott, Bahram Marami, Nina Shpalensky, Krystal Cascetta, Mary Sawyer, Monica Chan, Giovanni Koll, Alexander Shtabsky, Aaron Feliz, Thomas Hansen, Brandon Veremis, Carlos Cordon-Cardo, Jack Zeineh…
    Citation: Breast Cancer Research 2022 24:93
  20. This study explores the relationship between the E3 ubiquitin ligase Ring finger protein 126 (RNF126) and early breast cancer metastasis and tests the hypothesis that RNF126 determines the efficacy of inhibito...

    Authors: You Pan, Yuchao Yang, Rong Huang, Huawei Yang, Qinghua Huang, Yinan Ji, Jingxing Dai, Kun Qiao, Wei Tang, Longgui Xie, Ming Yin, Jun Ouyang, Shipeng Ning and Danke Su
    Citation: Breast Cancer Research 2022 24:92
  21. Childhood adiposity is inversely associated with young adult percent dense breast volume (%DBV) and absolute dense breast volume (ADBV), which could contribute to its protective effect for breast cancer later ...

    Authors: Joanne F. Dorgan, Heather J. Baer, Kimberly A. Bertrand, Erin S. LeBlanc, Seungyoun Jung, Laurence S. Magder, Linda G. Snetselaar, Victor J. Stevens, Yuji Zhang and Linda Van Horn
    Citation: Breast Cancer Research 2022 24:91
  22. Multiple clinical trials demonstrate consistent but modest benefit of adjuvant extended endocrine therapy (EET) in HR + breast cancer patients. Predictive biomarkers to identify patients that benefit from EET ...

    Authors: Dennis C. Sgroi, Kai Treuner, Yi Zhang, Tammy Piper, Ranelle Salunga, Ikhlaaq Ahmed, Lucy Doos, Sarah Thornber, Karen J. Taylor, Elena Brachtel, Sarah Pirrie, Catherine A. Schnabel, Daniel Rea and John M. S. Bartlett
    Citation: Breast Cancer Research 2022 24:90
  23. We investigated the associations of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) with breast cancer risk by the status of COX-2 protein expression.

    Authors: Lusine Yaghjyan, A. Heather Eliassen, Graham Colditz, Bernard Rosner, Pepper Schedin, Akemi Wijayabahu and Rulla M. Tamimi
    Citation: Breast Cancer Research 2022 24:89
  24. Up to 40% of patients with estrogen receptor-positive (ER+) breast cancer experience relapse. This can be attributed to breast cancer stem cells (BCSCs), which are known to be involved in therapy resistance, r...

    Authors: Svetlana E. Semina, Luis H. Alejo, Shivani Chopra, Nidhi S. Kansara, Irida Kastrati, Carol A. Sartorius and Jonna Frasor
    Citation: Breast Cancer Research 2022 24:88
  25. The worldwide incidence of invasive breast cancer in women is increasing according to several studies. This increase in incidence seems to be higher in young women (< 40 years). However, the reasons for this t...

    Authors: Yanis Hassaine, Emmanuelle Jacquet, Arnaud Seigneurin and Patricia Delafosse
    Citation: Breast Cancer Research 2022 24:87
  26. Terminal duct lobular units (TDLUs) are the structures in the breast that give rise to most breast cancers. Previous work has shown that TDLU involution is inversely associated with TDLU metrics, such as TDLU ...

    Authors: Brittny C. Davis Lynn, Brittany D. Lord, Renata Cora, Ruth M. Pfeiffer, Scott Lawrence, Gary Zirpoli, Traci N. Bethea, Julie R. Palmer and Gretchen L. Gierach
    Citation: Breast Cancer Research 2022 24:86
  27. There is a strong correlation between the morphological features of new tumor vessels and malignancy. However, angiogenic heterogeneity necessitates 3D microvascular data of tumor microvessels for more reliabl...

    Authors: Juanjuan Gu, Redouane Ternifi, Soroosh Sabeti, Nicholas B. Larson, Jodi M. Carter, Robert T. Fazzio, Mostafa Fatemi and Azra Alizad
    Citation: Breast Cancer Research 2022 24:85
  28. Breast cancer and its therapies frequently result in significant musculoskeletal morbidity. Skeletal complications include bone metastases, pain, bone loss, osteoporosis, and fracture. In addition, muscle loss...

    Authors: Tarah J. Ballinger, William R. Thompson and Theresa A. Guise
    Citation: Breast Cancer Research 2022 24:84
  29. Intraoperative electron radiotherapy (IOERT) can be used to treat early breast cancer during the conservative surgery thus enabling shorter overall treatment times and reduced irradiation of organs at risk. We...

    Authors: Catherine Philippson, Samuel Larsen, Stéphane Simon, Christophe Vandekerkhove, Alex De Caluwe, Dirk Van Gestel, Marie Chintinne, Isabelle Veys, Filip De Neubourg, Danièle Noterman, Mirela Roman, Jean-Marie Nogaret and Antoine Desmet
    Citation: Breast Cancer Research 2022 24:83
  30. Authors: Daniele Giardiello, Maartje J. Hooning, Michael Hauptmann, Renske Keeman, B. A. M. Heemskerk-Gerritsen, Heiko Becher, Carl Blomqvist, Stig E. Bojesen, Manjeet K. Bolla, Nicola J. Camp, Kamila Czene, Peter Devilee, Diana M. Eccles, Peter A. Fasching, Jonine D. Figueroa, Henrik Flyger…
    Citation: Breast Cancer Research 2022 24:82

    The original article was published in Breast Cancer Research 2022 24:69

  31. The biological phenotype of tumours evolves during neoadjuvant chemotherapy (NAC). Accurate prediction of pathological complete response (pCR) to NAC in the early-stage or posttreatment can optimize treatment ...

    Authors: Lei Wu, Weitao Ye, Yu Liu, Dong Chen, Yuxiang Wang, Yanfen Cui, Zhenhui Li, Pinxiong Li, Zhen Li, Zaiyi Liu, Min Liu, Changhong Liang, Xiaotang Yang, Yu Xie and Ying Wang
    Citation: Breast Cancer Research 2022 24:81
  32. The vast majority of research studies that have described the links between DNA damage repair or homologous recombination deficiency (HRD) score, and tumor biology, have concerned either triple negative breast...

    Authors: Elise Ballot, Loïck Galland, Hugo Mananet, Romain Boidot, Laurent Arnould, Isabelle Desmoulins, Didier Mayeur, Courèche Kaderbhai, Silvia Ilie, Audrey Hennequin, Anthony Bergeron, Valentin Derangère, François Ghiringhelli, Caroline Truntzer and Sylvain Ladoire
    Citation: Breast Cancer Research 2022 24:80
  33. Breast tumor immune infiltration is clearly associated with improved treatment response and outcomes in breast cancer. However, modifiable patient factors associated with breast cancer immune infiltrates are p...

    Authors: Sarah Asad, Adrienne Damicis, Yujing J. Heng, Kathryn Kananen, Katharine A. Collier, Elizabeth J. Adams, Kevin H. Kensler, Gabrielle M. Baker, Robert Wesolowski, Sagar Sardesai, Margaret Gatti-Mays, Bhuvaneswari Ramaswamy, A. Heather Eliassen, Susan E. Hankinson, Fred K. Tabung, Rulla M. Tamimi…
    Citation: Breast Cancer Research 2022 24:78
  34. Associations of birthweight, childhood body size and pubertal timing with breast cancer risks by menopausal status and tumor receptor subtypes are inconclusive. Thus, we investigated these associations in a po...

    Authors: Dorthe C. Pedersen, Britt W. Jensen, Anne Tjønneland, Zorana J. Andersen, Lene Mellemkjaer, Lise G. Bjerregaard, Julie Aarestrup and Jennifer L. Baker
    Citation: Breast Cancer Research 2022 24:77
  35. Breast parenchymal texture features, including grayscale variation (V), capture the patterns of texture variation on a mammogram and are associated with breast cancer risk, independent of mammographic density ...

    Authors: Yuxi Liu, Hongjie Chen, John Heine, Sara Lindstrom, Constance Turman, Erica T. Warner, Stacey J. Winham, Celine M. Vachon, Rulla M. Tamimi, Peter Kraft and Xia Jiang
    Citation: Breast Cancer Research 2022 24:76
  36. Breast cancer is a heterogenous disease with several histological and molecular subtypes. Models that represent these subtypes are essential for translational research aimed at improving clinical strategy for ...

    Authors: Ludmila Szabova, Melanie B. Gordon, Lucy Lu, Nathan Pate, Laura Bassel, Anthony J. Iacovelli, Baktiar Karim, Philip J. Homan, Deborah B. Householder, Theresa M. Guerin, Sandra Burkett, Amanda M. Day, Wendi Custer and Zoe Weaver Ohler
    Citation: Breast Cancer Research 2022 24:75
  37. The United States Food and Drug Administration recently approved a Ki-67 immunohistochemistry (IHC) assay to identify patients with early breast cancer at high disease recurrence risk. The Oncotype Dx Breast R...

    Authors: Michael Crager, Sameera R. Wijayawardana, Aaron M. Gruver, Andrea Blacklock, Christy Russell, Frederick L. Baehner and Francisco Sapunar
    Citation: Breast Cancer Research 2022 24:74
  38. The tumor immune microenvironment (TIME) generated by cancer-infiltrating immune cells has a crucial role in promoting or suppressing breast cancer progression. However, whether the steroid receptor coactivato...

    Authors: Sang Jun Han, Nuri Sung, Jin Wang, Bert W. O’Malley and David M. Lonard
    Citation: Breast Cancer Research 2022 24:73
  39. Metastatic breast cancer (MBC) is an incurable disease and its treatment focuses on prolonging patients’ (pts) overall survival (OS) and improving their quality of life. Eribulin is a microtubule inhibitor tha...

    Authors: Nicla La Verde, Giovanna Damia, Ornella Garrone, Daniele Santini, Alessandra Fabi, Mariangela Ciccarese, Daniele Giulio Generali, Martina Nunzi, Elena Poletto, Elisa Ferraris, Elisabetta Cretella, Giuseppa Scandurra, Icro Meattini, Alessandro Stefano Bertolini, Luigi Cavanna, Elena Collovà…
    Citation: Breast Cancer Research 2022 24:71
  40. Metastatic breast carcinoma is commonly considered during differential diagnosis when metastatic disease is detected in females. In addition to the tumor morphology and documented clinical history, sensitive a...

    Authors: Tian Du, Lu Pan, Chengyou Zheng, Keming Chen, Yuanzhong Yang, Jiewei Chen, Xue Chao, Mei Li, Jiabin Lu, Rongzhen Luo, Jinhui Zhang, Yu Wu, Jiehua He, Dongping Jiang and Peng Sun
    Citation: Breast Cancer Research 2022 24:70
  41. Prediction of contralateral breast cancer (CBC) risk is challenging due to moderate performances of the known risk factors. We aimed to improve our previous risk prediction model (PredictCBC) by updated follow...

    Authors: Daniele Giardiello, Maartje J. Hooning, Michael Hauptmann, Renske Keeman, B. A. M. Heemskerk-Gerritsen, Heiko Becher, Carl Blomqvist, Stig E. Bojesen, Manjeet K. Bolla, Nicola J. Camp, Kamila Czene, Peter Devilee, Diana M. Eccles, Peter A. Fasching, Jonine D. Figueroa, Henrik Flyger…
    Citation: Breast Cancer Research 2022 24:69

    The Correction to this article has been published in Breast Cancer Research 2022 24:82

  42. Ductal carcinoma in situ (DCIS) is the most common type of in situ premalignant breast cancers. What drives DCIS to invasive breast cancer is unclear. Basal-like invasive breast cancers are aggressive. We have...

    Authors: Ze-Yi Zheng, Hanan Elsarraj, Jonathan T. Lei, Yan Hong, Meenakshi Anurag, Long Feng, Hilda Kennedy, Yichao Shen, Flora Lo, Zifan Zhao, Bing Zhang, Xiang H.-F. Zhang, Ossama W. Tawfik, Fariba Behbod and Eric C. Chang
    Citation: Breast Cancer Research 2022 24:68
  43. Rating lymphocytes (TILs) are a prognostic marker in breast cancer and high TIL infiltration correlates with better patient outcomes. Meanwhile, parameters involving immune cells in peripheral blood have also ...

    Authors: Hiroko Onagi, Yoshiya Horimoto, Asumi Sakaguchi, Daiki Ikarashi, Naotake Yanagisawa, Takayuki Nakayama, Tetsuya Nakatsura, Yumiko Ishizuka, Ritsuko Sasaki, Junichiro Watanabe, Mitsue Saito, Harumi Saeki, Takuo Hayashi, Atsushi Arakawa, Takashi Yao and Shigehisa Kitano
    Citation: Breast Cancer Research 2022 24:67
  44. Breast cancer (BC) has the highest cancer incidence and mortality in women worldwide. Observational epidemiological studies suggest a positive association between testosterone, estradiol, dehydroepiandrosteron...

    Authors: Aayah Nounu, Siddhartha P. Kar, Caroline L. Relton and Rebecca C. Richmond
    Citation: Breast Cancer Research 2022 24:66
  45. Ribosomal biogenesis and ribosomal proteins have attracted attention in the context of tumor biology in recent years. Instead of being mere translational machineries, ribosomes might play an active role in tum...

    Authors: Anne-Marie Lüchtenborg, Patrick Metzger, Miguel Cosenza Contreras, Victor Oria, Martin L. Biniossek, Franziska Lindner, Klemens Fröhlich, Ambrus Malyi, Thalia Erbes, Nicole Gensch, Jochen Maurer, Andreas Thomsen, Melanie Boerries, Oliver Schilling, Martin Werner and Peter Bronsert
    Citation: Breast Cancer Research 2022 24:65
  46. Papillomas of the breast pose challenges for treatment decisions as their risk for transformation to breast cancer is low but not negligible. To spare low-risk patients the burden of substantial treatment side...

    Authors: Piotr Ziółkowski, Marta Woźniak, Ahmad Mansour, Yu An and Georg F. Weber
    Citation: Breast Cancer Research 2022 24:64
  47. Breast cancer cell lines (BCCLs) and patient-derived xenografts (PDXs) are the most frequently used models in breast cancer research. Despite their widespread usage, genome sequencing of these models is incomp...

    Authors: Niantao Deng, Andre Minoche, Kate Harvey, Meng Li, Juliane Winkler, Andrei Goga and Alex Swarbrick
    Citation: Breast Cancer Research 2022 24:63

Annual Journal Metrics